Table 1
From: Treatment of advanced thyroid cancer refractory to therapy
Drug name | Mechanism of action | Clinical trials (phase) | Indications |
|---|---|---|---|
MOTESANIB | VEGFR1,2,3, PDGFR, c-KIT, RET | II | MTC, DTC |
SORAFENIB | B-RAF, VEGFR1, VEGFR2 | II/III | MTC |
AXITINIB | VEGFR, c-KIT, PDGFR-B | II | DTC |
SUNITINIB | VEGFR1, 2, PDGFR, c-KIT, FLT3, RET | II | DTC |
LENVATINIB | VEGFR1,2,3, FGFR1 PDGFR | II/III | MTC |
CABOZANTINIB | MET, VEGFR2, RET | III | DTC |
PAZOPANIB | VEGFR, PDGFR, c-KIT | II | MTC |
VANDETANIB | RET, VEGFR, VEGFR2, EGFR | II | DTC |